Troglitazone and Simvastatin: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 4, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Simvastatin
Troglitazone
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
If you take simvastatin (a cholesterol-lowering statin) along with troglitazone, the troglitazone can speed up the liver enzyme that breaks down simvastatin. That means your body may clear the statin a little faster, so it may not lower your cholesterol as much as expected.
The good news is this is considered a minor interaction, and it builds up slowly rather than causing a sudden problem. Your care team can easily handle it by checking your cholesterol numbers and adjusting your statin dose if needed. Keep taking both medicines as prescribed, and ask your pharmacist or doctor if you have questions.
Effect: Reduced simvastatin lipid-lowering efficacy.
Mechanism: Troglitazone induces CYP3A4, increasing simvastatin metabolism and lowering active drug exposure (AUC). Simvastatin does not significantly alter troglitazone PK. Neither agent's activation is impaired here; this is loss of parent/active statin exposure via enzyme induction.
Onset: Delayed (enzyme induction). Evidence: Probable; clinical observation showed absence of an expected additional ~11% LDL reduction. Severity: Minor.
- Monitor lipid panel after initiating or during concurrent therapy.
- Higher simvastatin doses may be required; individualize titration to lipid targets.
- Consider a statin less dependent on CYP3A4 if response remains inadequate.
What happens
Decreased simvastatin efficacy
Interaction Deep Dive
When patients taking troglitazone were switched from pravastatin to simvastatin, no meaningful decreases in total and LDL cholesterol occurred, even though a further 11% reduction had been anticipated. This diminished lipid-lowering response to simvastatin in troglitazone-treated patients may be attributable to troglitazone inducing cytochrome P450 3A4 (CYP3A4) enzymes, which handle the metabolism of simvastatin1. The pharmacokinetics of troglitazone were not significantly altered by simvastatin3.
Why it happens (mechanism)
Induction of cytochrome P450 3A4-mediated simvastatin metabolism
How to manage this interaction
This is a minor, manageable interaction. Troglitazone can make simvastatin work a bit less, so your cholesterol may not drop as much as expected.
- Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise.
- Your team may check your cholesterol (lipid) levels more closely to see how well the statin is working.
- Your simvastatin dose may need to be adjusted and individualized by your care team to keep it effective.
Ask your pharmacist or doctor to review your cholesterol results and let them know about any new medications.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A retrospective study was performed involving 344 patients with diabetes who were separated into two groups. The troglitazone group consisted of 21 patients receiving troglitazone both before and after being switched from comparable doses of pravastatin to simvastatin, while the non-troglitazone group comprised 323 patients. Patients taking troglitazone showed no meaningful decreases in total and LDL cholesterol when they were switched from pravastatin to simvastatin, even though an additional 11% reduction had been anticipated 1.
b) A case report has been described of a patient who developed severe hepatitis and myositis eight weeks after troglitazone was added to a previously stable regimen of simvastatin. A 68-year-old woman with type 2 diabetes mellitus and hypercholesterolemia had, on her own initiative, resumed troglitazone 200 mg twice daily for 8 weeks after her metformin supply ran out. She had received simvastatin for three years. Her initial laboratory values were: AST 546 IU/L, ALT 437 IU/L, alkaline phosphatase 109 IU/L, total bilirubin 4.5 mg/dL, albumin 2.5 mg/dL, total protein 7.6 gm/dL, glucose 275 mg/dL, creatine kinase 14,300 IU/L, hemoglobin 12.9 g/dL, platelet 88,000/microliter, prothrombin 18.1 sec, and cholesterol 117 mg/dL. Examination of the ascites fluid showed cirrhosis. Electromyography of the lower extremities showed muscle inflammation and necrosis. Across a span of 12 weeks the myositis resolved; however, the hepatitis advanced to symptomatic cirrhosis. The author concludes that the underlying pathogenic mechanism is altered mitochondrial metabolism, producing combined severe toxicity to both liver and skeletal muscle 2.
c) Coadministration of troglitazone and simvastatin produced a modest reduction in both the area under the plasma concentration-time profiles (AUC) and the maximum plasma concentrations (Cmax) of HMG-CoA reductase inhibitors, by 30% and 40%, respectively. In an open-label, randomized, multiple-dose, two-period crossover study of 12 subjects, each subject was given troglitazone 400 mg daily for 24 days with simvastatin 40 mg on days 15 through 24. In Treatment B, subjects received simvastatin 40 mg daily for 10 days. Mean plasma concentrations of simvastatin were significantly higher (p less than 0.05) for simvastatin given alone (Treatment B) than those measured after administration of simvastatin together with troglitazone (Treatment A). The AUC and Cmax for active and total HMG-CoA reductase inhibitors were decreased by troglitazone treatment. No significant differences (p equal to 0.677) were seen in plasma troglitazone AUC values with or without simvastatin. Cmax was significantly higher for troglitazone with simvastatin than for troglitazone alone. The authors conclude that these findings are consistent with the documented capacity of troglitazone to lower plasma concentrations of several CYP3A4 substrates through induction of CYP3A4, the enzyme responsible for simvastatin metabolism. Simvastatin did not significantly change the pharmacokinetics of troglitazone, supporting that simvastatin is not an inhibitor of drug metabolizing enzymes 3.
Common questions
Can I take Troglitazone and Simvastatin together?
Troglitazone can make simvastatin less effective at lowering cholesterol by speeding up its breakdown, but this is minor and easily managed with lipid monitoring and, if needed, a dose adjustment by your care team. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Troglitazone and Simvastatin interaction?
It is rated minor. Usually limited clinical impact.
How quickly could this interaction happen?
The documented onset is "delayed". Effects tend to build up gradually over days to weeks.
How is the Troglitazone and Simvastatin interaction managed?
This is a minor, manageable interaction. Troglitazone can make simvastatin work a bit less, so your cholesterol may not drop as much as expected. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Your team may check your cholesterol (lipid) levels more closely to see how well the statin is working. Your simvastatin dose may need to be adjusted and individ… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Troglitazone or Simvastatin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (3)
- Lin JC & Ito MK: A drug interaction between troglitazone and simvastatin. Diabetes Care 1999; 22:2104-2105. PubMed
- Caldwell S, Hespenheide E, & Borstel R: Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001; 46(2):376-378.
- Prueksaritanont T, Vega J, Zhao J, et al: Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2001; 41:573-581. PubMed
Keep reading about Simvastatin
Keep reading about Troglitazone
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist